Published in Blood Weekly, June 13th, 2002
Dr. Rupert Handgretinger and colleagues at the Children's University Hospitals of Tuebingen, Koeln, and Frankfurt, and Olgahospital Stuttgart in Stuttgart, Germany, evaluated the safety and efficacy of positive CD34 selection in removing tumor cells from hematopoietic stem cell grafts.
This purging method is effective without degrading the graft's ability to engender hematopoietic reconstitution, Handgretinger and coauthors found.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.